Method of identifying patients not suitable for high-dose cyclophosphamide treatment
The present invention provides methods of identifying subjects that are suitable and not suitable for high-dose cyclophosphamide treatment.
1. A method for identifying a subject suitable for high-dose cyclophosphamide treatment, comprising measuring the amount or activity of aldehyde dehydrogenase (ALDH) from peripheral lymphocytes from a sample from said subject, wherein the subject is identified as being suitable for high-dose cyclophosphamide treatment if the amount or activity of ALDH is less than the amount or activity of ALDH which confers resistance of the peripheral lymphocytes to high-dose cyclophosphamide treatment, and administering cyclophosphamide to the subject.
2. The method of claim 1 , wherein the high-dose cyclophosphamide treatment is used to treat an autoimmune disease.
3. The method of claim 1 , wherein the high-dose cyclophosphamide treatment is used to treat cancer.
4. The method of claim 1 , wherein the sample comprises a bone marrow aspirate.
5. The method of claim 1 , wherein the sample comprises banked blood.
6. The method of claim 1 , wherein the amount or activity of ALDH is measured using flow cytometry.
7. The method of claim 1 , wherein the amount or activity of ALDH is measured using western blot analysis.
8. The method of claim 1 , wherein the amount or activity of ALDH is measured using dansyl aminoacetaldehyde (DAAA) as a substrate.
9. The method of claim 1 , wherein the amount or activity of ALDH is measured using boron-dipyrromethene (BODIPY) aminoacetaldehyde (BAAA) as a substrate.
10. The method of claim 1 , wherein the amount or activity of ALDH is measured using a substrate for ALDH that yields a fluorescent molecule which is detected using flow cytometry.